Ranibizumab Injection for Corneal Neovascularization Refractory to Bevacizumab Treatment
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseaseswith neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumabor ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractorycorneal NV despite two previous subconjunctival and intrastromal bevacizumab injections, received twosubconjunctival and intrastromal ranibizumab injections. Six months postoperatively, there was significantregression of the neovascular area and vessel caliber. Here, the authors report a case of improvement incorneal NV with subconjunctival and intrastromal ranibizumab injections, which was previously refractory tobevacizumab injection. The findings may suggest a new prospect in treating corneal NV.
Abstract
Vascular endothelial growth factor inhibitor is an emerging therapeutic modality for various ocular diseaseswith neovascularization (NV). However, for corneal NV, controversy remains regarding whether bevacizumabor ranibizumab is superior. A 32-year-old female diagnosed with herpetic keratoconjunctivitis with refractorycorneal NV despite two previous subconjunctival and intrastromal bevacizumab injections, received twosubconjunctival and intrastromal ranibizumab injections. Six months postoperatively, there was significantregression of the neovascular area and vessel caliber. Here, the authors report a case of improvement incorneal NV with subconjunctival and intrastromal ranibizumab injections, which was previously refractory tobevacizumab injection. The findings may suggest a new prospect in treating corneal NV.
참고문헌 (20)
- Chang JH, "Corneal neovascularization", Curr Opin Ophthalmol, 12, pp.242~249 (2001)
- Azar DT, "Corneal angiogenic privilege: angiogenic and antiangiogenic factors in corneal avascularity, vasculogenesis, and wound healing (an American Ophthalmological Society thesis)", Trans Am Ophthalmol Soc, 104, pp.264~302 (2006)
- Cursiefen C, "Consensus statement on indications for anti-angiogenic therapy in the management of corneal diseases associated with neovascularisation:outcome of an expert roundtable", Br J Ophthalmol, 96, pp.3~9 (2012)
- Ellenberg D, "Novel aspects of corneal angiogenic and lymphangiogenic privilege", Prog Retin Eye Res, 29, pp.208~248 (2010)
- Gabison E, "Anti-angiogenic role of angiostatin during corneal wound healing", Exp Eye Res, 78, pp.579~589 (2004)
- Hanahan D, "Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis", Cell, 86, pp.353~364 (1996)
- Carmeliet P, "Molecular mechanisms and clinical applications of angiogenesis", Nature, 473, pp.298~307 (2011)
- Stevenson W, "Corneal neovascularization and the utility of topical VEGF inhibition:ranibizumab (Lucentis) vs bevacizumab (Avastin)", Ocul Surf, 10, pp.67~83 (2012)
- Ferrari G, "Topical ranibizumab as a treatment of corneal neovascularization", Cornea, 32, pp.992~997 (2013)
- Epstein RJ, "Corneal neovascularization. Pathogenesis and inhibition", Cornea, 6, pp.250~257 (1987)
- Jorgensen KA, "Hydrocortisone inhibits platelet prostaglandin and endothelial prostacyclin production", Pharmacol Res Commun, 13, pp.579~586 (1981)
- Frucht J, "Topical indomethacin effect on neovascularisation of the cornea and on prostaglandin E2levels", Br J Ophthalmol, 68, pp.656~659 (1984)
- Pai VH, "Necrotizing scleritis following laser therapy for corneal vascularization", Ann Ophthalmol, 41, pp.50~51 (2009)
- Solomon A, "Long-term outcome of keratolimbal allograft with or without penetrating keratoplasty for total limbal stem cell deficiency", Ophthalmology, 109, pp.1159~1166 (2002)
- Kheirkhah A, "Sutureless amniotic membrane transplantation for partial limbal stem cell deficiency", Am J Ophthalmol, 145, pp.787~794 (2008)
- Ferrara N, "Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer", Nat Rev Drug Discov, 3, pp.391~400 (2004)
- Nomoto H, "Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits", Invest Ophthalmol Vis Sci, 50, pp.4807~4813 (2009)
- Rocher N, "Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes", Mol Vis, 17, pp.104~ (2011)
- Dastjerdi MH, "Corneal penetration of topical and subconjunctival bevacizumab", Invest Ophthalmol Vis Sci, 52, pp.8718~8723 (2011)
- Hashemian MN, "Prevention of corneal neovascularization: comparison of different doses of subconjunctival bevacizumab with its topical form in experimental rats", Ophthalmic Res, 46, pp.50~54 (2011)